Mayo Clinic Aortic Center, Advanced Endovascular Aortic Research Program, Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
Mayo Clinic Aortic Center, Advanced Endovascular Aortic Research Program, Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
J Vasc Surg. 2020 Aug;72(2):445-455. doi: 10.1016/j.jvs.2019.09.055. Epub 2020 Jan 21.
The objective of this study was to determine the incidence rate, outcomes, and risk factors of target vessel-related endoleaks after fenestrated-branched endovascular aortic repair (F-BEVAR) for pararenal aneurysms or thoracoabdominal aortic aneurysms (TAAAs).
We reviewed consecutive patients treated by F-BEVAR between 2007 and 2017. Target vessel endoleaks were identified by computed tomography angiography (CTA). Follow-up included CTA and duplex ultrasound before discharge, at 2 months, at 6 months, and annually thereafter. Primary endoleaks were detected by predismissal CTA; secondary endoleaks were absent on the first CTA and were identified during follow-up. End points were spontaneous resolution of primary endoleaks, secondary interventions, and aneurysm rupture. Multivariable analyses were performed for risk factors of target vessel endoleaks and predictors of spontaneous resolution.
A total of 382 patients (mean age, 75 ± 8 years; 75% male) underwent F-BEVAR for 195 pararenal aneurysms and 187 TAAAs with 1204 renal-mesenteric arteries targeted by 981 fenestrations and 223 directional branches. Fifty-two target vessel endoleaks were identified in 41 patients; 41 were type IIIC (interattachment), 10 were type IC (distal bridging stent sealing zone), and 1 was type IIIB (bridging stent fabric tear). Thirty-three patients (9%) had primary target vessel endoleaks in 41 target vessels (3%). Eight patients (2%) developed 11 secondary target vessel endoleaks. Directional branches were more prone to primary endoleaks (13/223 [6%]) in comparison to fenestrations (28/981 [3%]; P = .03). However, branch endoleaks resolved more often spontaneously (11/14 [79%]) compared with fenestration endoleaks (14/38 [37%]; P = .008). Other risk factors for target vessel endoleaks included inner aortic diameter ≥30 mm at the target vessel origin, four or more targeted vessels, TAAA (for primary endoleaks), and physician-modified endograft (for secondary endoleaks). Four patients with primary endoleaks underwent successful reintervention before discharge, and 29 were observed with a mean follow-up of 24 ± 21 months. Of the 41 primary endoleaks, 25 resolved spontaneously in 20 patients (61%) at first follow-up with no recurrences. Of the observed endoleaks, 11 persisted in 9 patients, and 8 of those endoleaks were treated in 7 patients. All secondary target vessel endoleaks required reintervention. There was one possible aneurysm rupture attributed to persistent secondary target vessel endoleak.
Target vessel endoleak on CTA at discharge occurs in 1 of 10 patients treated by F-BEVAR. Of these, two-thirds resolve spontaneously, especially those affecting directional branches. Among patients with a persistent endoleak, endovascular reintervention is usually successful and aneurysm rupture is rare.
本研究旨在确定采用分支型腔内修复术(F-BEVAR)治疗肾周动脉瘤或胸腹主动脉瘤(TAAA)后,靶血管相关内漏的发生率、结局和风险因素。
我们回顾了 2007 年至 2017 年间接受 F-BEVAR 治疗的连续患者。通过计算机断层血管造影(CTA)确定靶血管内漏。随访包括出院前、术后 2 个月、6 个月及此后每年的 CTA 和双功能超声检查。主要内漏在出院前的 CTA 中发现;次要内漏在第一次 CTA 中不存在,在随访中发现。终点为主要内漏自发消退、二次干预和动脉瘤破裂。采用多变量分析评估靶血管内漏的风险因素和自发消退的预测因素。
共有 382 例患者(平均年龄 75±8 岁;75%为男性)接受 F-BEVAR 治疗 195 例肾周动脉瘤和 187 例 TAAA,其中 1204 个肾-肠系膜动脉由 981 个开窗和 223 个定向分支靶向。41 例患者中的 41 个靶血管发现 52 个靶血管内漏,其中 41 个为 IIIIC 型(连接性),10 个为 IC 型(远端桥接支架密封区),1 个为 IIIB 型(桥接支架织物撕裂)。41 个靶血管中有 33 个(3%)发生 33 例(9%)患者的主要靶血管内漏。8 例(2%)发生 11 例次次要靶血管内漏。定向分支发生主要内漏的几率(13/223 [6%])高于开窗(28/981 [3%];P=.03)。然而,分支内漏自发消退的几率更高(11/14 [79%]),而开窗内漏为(14/38 [37%];P=.008)。靶血管内漏的其他风险因素包括靶血管起始处主动脉内径≥30mm、4 个以上目标血管、TAAA(主要内漏)和医生改良的移植物(次要内漏)。4 例主要内漏患者在出院前成功进行了再次干预,其余 29 例在平均 24±21 个月的随访中进行了观察。41 例主要内漏中,20 例(61%)患者在首次随访时自发消退 25 例,无复发。观察到的内漏中,9 例患者的 11 例持续存在,其中 8 例在 7 例患者中得到治疗。所有次要靶血管内漏均需再次干预。有一例可能的动脉瘤破裂归因于持续的次要靶血管内漏。
F-BEVAR 治疗后,CTA 显示出院时 10 例患者中有 1 例发生靶血管内漏。其中,三分之二自发消退,特别是影响定向分支的内漏。在持续存在内漏的患者中,血管内再介入通常是成功的,且动脉瘤破裂很少见。